Your browser doesn't support javascript.
loading
Impact of Tigecycline on C. difficile Outcomes: Case Series and Propensity-Matched Retrospective Study.
Phillips, Emma C; Warren, Cirle A; Ma, Jennie Z; Madden, Gregory R.
  • Phillips EC; University of Virginiagrid.27755.32 School of Medicine, Charlottesville, Virginia, USA.
  • Warren CA; Division of Infectious Diseases & International Health, Department of Medicine, University of Virginiagrid.27755.32 School of Medicine, Charlottesville, Virginia, USA.
  • Ma JZ; Department of Public Health Sciences, University of Virginiagrid.27755.32 Health System, Charlottesville, Virginia, USA.
  • Madden GR; Division of Infectious Diseases & International Health, Department of Medicine, University of Virginiagrid.27755.32 School of Medicine, Charlottesville, Virginia, USA.
Antimicrob Agents Chemother ; 66(6): e0000122, 2022 06 21.
Article en En | MEDLINE | ID: mdl-35647645
ABSTRACT
This case series and propensity-matched cohort study on the use of tigecycline in Clostridioides difficile infection (CDI) evaluated the effect of tigecycline on 30-day mortality. Adjusted for ATLAS Score, hypotension, treatment time period, and serum lactate, tigecycline did not significantly improve 30-day mortality (odds ratio 0.89; 95% confidence interval 0.25-3.12; P = 0.853). A randomized controlled trial is needed to determine efficacy and safety of tigecycline in severe or refractory CDI.
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Clostridioides difficile / Infecciones por Clostridium / Tigeciclina Tipo de estudio: Observational_studies Límite: Humans Idioma: En Año: 2022 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Clostridioides difficile / Infecciones por Clostridium / Tigeciclina Tipo de estudio: Observational_studies Límite: Humans Idioma: En Año: 2022 Tipo del documento: Article